Our response to COVID-19
Since the pandemic began, we have sought ways to harness our scientific expertise and technology to make a difference. Together with our partners we are developing COVID-19 therapeutics and vaccines, and now have assets at various stages of development, including two approved for use (in some countries).
We are collaborating with US immunology company, Vir Biotechnology, to investigate two monoclonal antibodies that target the COVID-19 virus.
Monoclonal antibodies are created in a lab by cloning an antibody that has been exposed to a specific virus. This enables multiple antibodies that will target the virus to be produced. Monoclonal antibodies work in a similar way to the human immune system and could be an important intervention for people who do not have a strong natural immune response to a virus.
In May 2021, we received Emergency Use Authorisation from the US Food and Drug Administration for the first of these monoclonal antibodies. In December 2021, the European Commission approved the same monoclonal antibody for use in the European Union.
The second antibody from our collaboration with Vir is also being investigated as a potential treatment. A phase 1/2 study in patients with mild to moderate COVID-19 is underway.
Adjuvanted COVID-19 vaccines
We partnered with several companies working on vaccines by providing them with access to our adjuvant technology.
Adding an adjuvant to a vaccine can improve the immune system’s response to the vaccine. This may allow for more doses to be produced because a smaller amount of vaccine is needed to generate immunity. This is valuable during a pandemic when a vaccine must be produced in large quantities.
One such partnership is with Sanofi. In February 2022, following phase 3 study results, we announced we would seek marketing authorisations.
Our collaboration with Canadian biopharmaceutical company, Medicago, created a unique vaccine using their plant-based technology. Following phase 3 results in December 2021, approval for use was granted by Health Canada in February 2022.
We are also collaborating with South Korean pharmaceutical company, SK bioscience, on a vaccine. Following phase 3 results in April 2022, we submitted a biologics license application to the Korean Ministry of Food and Drug Safety.
mRNA COVID-19 vaccines
In addition to our work on adjuvanted vaccines, we are working with CureVac to develop mRNA vaccines potentially effective against multiple COVID-19 variants. We announced encouraging pre-clinical test results in 2021 with clinical testing to begin in 2022.
This agreement builds on the existing relationship between GSK and CureVac to develop up to five mRNA-based vaccines and monoclonal antibodies. We have also made a £130m equity investment in CureVac.
Find out more
Guidance for clinical trial investigators
Conducting clinical research during the COVID-19 pandemic.
How we research new vaccines
We invest in scientific and technical excellence to develop and launch new innovative vaccines that meet the needs of patients and payers.
How we develop new vaccines
Our work to research, develop and introduce a new vaccine typically goes through several stages.
As a business, we are supporting global efforts to tackle the COVID-19 pandemic and protecting the safety of our people.